Stock ADTX ADITXT, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Aditxt, Inc.

Equities

ADTX

US0070256047

Market Closed - Nasdaq
Other stock markets
 21:30:00 10/05/2024 BST 		5-day change 1st Jan Change
2.07 USD 0.00% Intraday chart for Aditxt, Inc. -10.00% -68.78%
05-03 Aditxt, Inc. announced that it expects to receive $4.2 million in funding CI
05-02 Aditxt, Inc. announced that it expects to receive $150 million in funding CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
AQ
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
BU
Aditxt, Inc. announced that it expects to receive $4.2 million in funding
CI
Aditxt, Inc. announced that it expects to receive $150 million in funding
CI
Aditxt, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Appili Therapeutics Signs Definitive Agreement to be acquired by Aditxt, Inc.
AQ
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense
AQ
Appili Therapeutics To be Acquired by Aditxt, Inc.
MT
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
BU
Evofem Biosciences - For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
AQ
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
PR
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
PR
Aditxt, Inc. Acquires Proprietary Electroencephalography Brain Monitoring Technologies and Devices, Including NeuroCap and NeuroEEG for Telehealth and Tele-neurology Applications
AQ
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
BU
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
AQ
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
AQ
Aditxt, Inc.’s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.’s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
BU
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
BU
Aditxt, Inc. announced that it has received $6.000003 million in funding
CI
Aditxt, Inc. Regains Compliance with Nasdaq Stockholders Equity Requirement
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ADTX Stock
  4. News Aditxt, Inc.